Developing drugs for developing countries.
Repository Usage Stats
Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.
Health Services Accessibility
Orphan Drug Production
Patents as Topic
United States Food and Drug Administration
Published Version (Please cite this version)10.1377/hlthaff.25.2.313
Publication InfoRidley, David; & Moe, Jeffrey (2006). Developing drugs for developing countries. Health Aff (Millwood), 25(2). pp. 313-324. 10.1377/hlthaff.25.2.313. Retrieved from https://hdl.handle.net/10161/7017.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Adjunct Professor of Global Health
Professor of the Practice of Business Adminstration
David Ridley is the Faculty Director of Health Sector Management at Duke University’s Fuqua School of Business. In his research, he examines innovation and pricing in health care. David was the lead author of the paper proposing the priority review voucher program which became law in 2007 and created
Alphabetical list of authors with Scholars@Duke profiles.